Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 178 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vaccines, Pneumococcal Clear all
Completed Phase 4 Interventional Results available

Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease

NCT01974817
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
13-valent conjugate pneumococcal vaccine
Biological
Lead sponsor
Michigan State University
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants

NCT03512288
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, 13vPnC
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
39
States / cities
Fayetteville, Arkansas • Downey, California • Huntington Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 12, 2026, 2:10 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of wSp Vaccine in Young Children

NCT07216430
View directory record Official record
Conditions
Acute Otitis Media (AOM)
Interventions
wSp vaccine, Saline (0.9% NaCl)
Biological
Lead sponsor
Serum Life Science Europe GmbH
Industry
Eligibility
5 Months to 7 Months
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
7
States / cities
Pittsford, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

NCT00046852
View directory record Official record
Conditions
Infection, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, pneumococcal polyvalent vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, carmustine, cyclophosphamide, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 12, 2026, 2:10 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06736041
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, RotaTeq, Vaxelis vaccine, Varivax, Hexaxim Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
1,714 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
66
States / cities
Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults

NCT07059182
View directory record Official record
Conditions
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
Interventions
Inactivated whole-cell Streptococcus pneumoniae vaccine, Placebo
Biological · Drug
Lead sponsor
Serum Life Science Europe GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 12, 2026, 2:10 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

NCT03729778
View directory record Official record
Conditions
HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections
Interventions
Prevnar-13
Biological
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
21 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine

NCT00589394
View directory record Official record
Conditions
Healthy
Interventions
pneumococcal vaccination (Pneumovax)
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 12, 2026, 2:10 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses

NCT06128915
View directory record Official record
Conditions
Aging
Interventions
vaccine
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

NCT04379713
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
1,511 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
41
States / cities
Tucson, Arizona • Fullerton, California • Oxnard, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

NCT05420961
View directory record Official record
Conditions
Pneumonia, Pneumococcal
Interventions
V116, PCV15, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
717 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Glendale, Arizona • Tempe, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)

NCT06177912
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V116, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Madera, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults

NCT01537185
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
Placebo, SPWCV+Alum 100 mcg, SPWCV+Alum 600 mcg, SPWCV+Alum 300 mcg
Other · Biological
Lead sponsor
PATH Vaccine Solutions
Other
Eligibility
18 Years to 40 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

NCT03207750
View directory record Official record
Conditions
Rotavirus Infection, Rotavirus Vaccines
Interventions
Rotarix, Pediarix, Hiberix, Prevenar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
47
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study Evaluating Pneumococcal Vaccine in Healthy Infants

NCT00205803
View directory record Official record
Conditions
Healthy Subjects, Pneumococcal Infections
Interventions
13-Valent Pneumococcal Conjugate Vaccine (13vPnC), 7-Valent Pneumococcal Conjugate Vaccine (7vPnC)
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2012 · Synced Sep 12, 2026, 2:10 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants

NCT06524414
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
605 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
61
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • La Puente, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 12, 2026, 2:10 AM EDT
Recruiting Phase 2 Interventional

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

NCT05183854
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine
Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 12, 2026, 2:10 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine

NCT06337643
View directory record Official record
Conditions
Pneumococcal Vaccine
Interventions
MVX01, MVX01 Placebo
Biological
Lead sponsor
Matrivax Research and Development Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Savannah, Georgia • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fever After Simultaneous Versus Sequential Vaccination in Young Children

NCT03165981
View directory record Official record
Conditions
Fever After Vaccination, Fever, Febrile Seizure
Interventions
PCV13, DTaP, IIV
Biological
Lead sponsor
Duke University
Other
Eligibility
12 Months to 16 Months
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Oakland, California • Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults

NCT00427895
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
26
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

NCT02045836
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster vaccine GSK 1437173A, Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Golden, Colorado • Wichita, Kansas • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

NCT04525599
View directory record Official record
Conditions
Healthy Volunteers, Pneumococcal Disease
Interventions
ASP3772, PCV13
Biological
Lead sponsor
Affinivax, Inc.
Industry
Eligibility
12 Months to 15 Months
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
17
States / cities
Bryant, Arkansas • Jonesboro, Arkansas • Anaheim, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

NCT02987972
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114 Lot 1, V114 Lot 2, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,051 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
30
States / cities
Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 12, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated

NCT01025336
View directory record Official record
Conditions
Healthy
Interventions
Blood draw
Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
962 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
29
States / cities
Chandler, Arizona • Phoenix, Arizona • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced Sep 12, 2026, 2:10 AM EDT